Aeterna Zentaris Inc. (AEZS)
After hours:
- GlobeNewswire
Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris
TORONTO and EDMONTON, Alberta, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna") and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased to announce that the Court of King's Bench of Alberta has issued a final order approving the arrangement described in the previously announced definitive agreement to combine the operations of Ceapro and Aeterna in an all-stock merger of equals transaction (the “Transaction”). The parties anticipate comple
- Zacks
Aeterna Zentaris (AEZS) Reports Q4 Loss, Tops Revenue Estimates
AEterna Zentaris (AEZS) delivered earnings and revenue surprises of -19.59% and 2,925%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
- Company confirms successful completion of enrollment in the pivotal DETECT Phase 3 trial - Company ended the year with $34.0 million in cash, expected to fund operations through 2024 and into 2025 - All-stock merger of equals transaction with Ceapro, Inc. expected to close in the second quarter of 2024 TORONTO, ONTARIO, March 27, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercia
